Theriva™ Biologics (NYSE American: TOVX), a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and related diseases in areas of high unmet need, today announced its selection as one of five finalists for the prestigious Advance Biotech Grant in the EMEA region, hosted by Merck KGaA. The selected finalists will present before a panel of six judges from Merck’s Emerging Biotech Group at BIO-Europe 2024 in Stockholm, Sweden.

Dr. Manel Cascalló, General Manager of Theriva Biologics’ EU subsidiary, will present an overview of VCN-01, currently in a Phase 2b clinical trial for first-line metastatic pancreatic cancer in combination with standard-of-care chemotherapy. Dr. Cascalló's presentation will take place on Monday, November 4, 2024, from 15:20 to 16:40 CET/CEST (GMT+2), where he will highlight the innovative mechanisms of action of VCN-01 and Theriva’s internal capabilities in developing its production process.

Merck KGaA’s EMEA Advance Biotech Grant program honors emerging biotech companies, providing recipients with financial support and expert guidance on the path to commercialization, including consultations with M Ventures. Following an active, multi-stage competition among various biotechnology companies and technologies, the five finalists will showcase their advancements to Merck KGaA representatives and attendees at BIO-Europe. The winner will be announced after all presentations.